{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:25Z","timestamp":1786119265025,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Epstein\u2013Barr virus-related posttransplant lymphoproliferative disorder (EBV-PTLD) is a serious and potentially fatal complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We report a case of a 46-year-old male who developed EBV-PTLD 3 months after haploidentical HSCT for refractory acute myeloid leukemia. The patient presented with a persistent cough and a pulmonary nodule that increased in size from 8 mm\u2005\u00d7\u20055\u2009mm to 27 mm\u2005\u00d7\u200525\u2009mm over 4 weeks. Increased EBV loads were also detected (peripheral blood EBV sorting: EBV-T DNA 2.09E+03, EBV-B DNA 1.16E+03, EBV-NK DNA 7.89E+02 copies\/mL; alveolar lavage fluid: 114 sequences; later rising to 3304).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Diagnosis was confirmed by biopsy which showed EBV-positive pleomorphic lymphoproliferative disorder with extensive necrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Treatment consisted of an oral regimen of chidamide (5\u2009mg once daily) and valganciclovir (450\u2009mg twice daily).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 8 weeks of therapy, the pulmonary lesion decreased to 19 mm\u2005\u00d7\u200516\u2009mm, and peripheral blood EBV-DNA levels declined significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>The patient achieved clinical remission with manageable side effects, including neutropenia and thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048412","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:02:47Z","timestamp":1777273367000},"page":"e48412","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Novel oral chidamide and valganciclovir regimen for EBV-PTLD post-hematopoietic stem cell transplantation: A case report"],"prefix":"10.1097","volume":"105","author":[{"given":"Yaogong","family":"Wu","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7697-405X","authenticated-orcid":false,"given":"Zhaodong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1038\/s41598-020-78259-5","article-title":"Impact of HLA class I allele-level mismatch on viral infection within 100 days after cord blood transplantation.","volume":"10","author":"Iemura","year":"2020","journal-title":"Sci Rep"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41409-020-0831-7","article-title":"Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.","volume":"55","author":"Ru","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","article-title":"Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"R4-20260622","first-page":"996","article-title":"A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.","volume":"46","author":"Xu","year":"2007","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R5-20260622","first-page":"904","article-title":"The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation.","volume":"42","author":"Niu","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R7-20260622","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","article-title":"Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b\/2 study.","volume":"7","author":"Haverkos","year":"2023","journal-title":"Blood Adv"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1358\/dot.2017.53.3.2595452","article-title":"Chidamide tablets: HDAC inhibition to treat lymphoma.","volume":"53","author":"Xu","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-Transplantation Lymphoproliferative Disorders in Adults.","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"101895","DOI":"10.1016\/j.trim.2023.101895","article-title":"Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: a case report and literature review.","volume":"80","author":"Chen","year":"2023","journal-title":"Transpl Immunol"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"101797","DOI":"10.1016\/j.trim.2023.101797","article-title":"The effects of encapsulation on NK cell differentiation potency of C-kit+ hematopoietic stem cells via identifying cytokine profiles.","volume":"77","author":"Farahzadi","year":"2023","journal-title":"Transpl Immunol"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","article-title":"A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.","volume":"18","author":"Banerji","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcmd.2006.10.008","article-title":"Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.","volume":"38","author":"Ghosh","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41409-023-02045-w","article-title":"Chidamide maintenance therapy in high-risk T-ALL\/T-LBL after allo-HSCT: a prospective, single-center, single-arm study.","volume":"58","author":"Guo","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R17-20260622","doi-asserted-by":"crossref","first-page":"849768","DOI":"10.3389\/fbioe.2022.849768","article-title":"An overview of autophagy in hematopoietic stem cell transplantation.","volume":"10","author":"Montazersaheb","year":"2022","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:14Z","timestamp":1786039694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":17,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048412","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}